Synexa Life Sciences established at the Leiden Bio Science ParkMonday, May 20, 2019
The establishment of Synexa Life Sciences BV marks an important step in the continued international expansion of the company, allowing it to be closer to its key clients and its expanding European biomarker laboratory operations. The new HQ will bring together scientific leadership, client relationship management and finance functions and will position the company well to further develop its biomarker services offering globally.
The new structure has been facilitated by an investment by Gilde Healthcare, a specialist European private equity healthcare investor, that has acquired the shareholding of the Industrial Development Corporation of South Africa (IDC). The company’s founding shareholders and current executive management team - Prof. Patrick Bouic (CSO), Dr. Justin Devine (CMO) and Paul O’Riordan (CEO) - remain in place as shareholders in the new company and fully committed to leading the company through this new and exciting chapter in its growth.